• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

评估直接口服抗凝剂与华法林相比在极重度肥胖非瓣膜性心房颤动患者中的疗效和安全性：一项回顾性队列研究

"Evaluating the efficacy and safety of direct oral anticoagulants compared to warfarin in very morbidly obese patients with non-valvular atrial fibrillation: A retrospective cohort study".

作者信息

Ezaldin Shady, Abdelsalam Mahmoud, Annie Frank, Chumbe Julton Tomanguillo, Gharib Elie

机构信息

Cardiovascular Department, Charleston Area Medical Center, Charleston, WV, USA.

出版信息

Heliyon. 2025 Jan 3;11(1):e41596. doi: 10.1016/j.heliyon.2024.e41596. eCollection 2025 Jan 15.

DOI:10.1016/j.heliyon.2024.e41596
PMID:39866424
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11758958/
Abstract

•DOACs are effective and safe in very morbidly obese AF patients (BMI ≥50 kg/m).•DOACs show similar stroke and bleeding risks as warfarin in this population.•Findings support DOACs in anticoagulation guidelines for very morbidly obese patients.

摘要

•直接口服抗凝剂（DOACs）在极度肥胖的房颤患者（体重指数≥50kg/m²）中有效且安全。

•在这一人群中，DOACs与华法林的中风和出血风险相似。

•研究结果支持在针对极度肥胖患者的抗凝指南中使用DOACs。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a121/11758958/f05796d4baf7/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a121/11758958/be22de8f6712/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a121/11758958/c40bc0a31ee3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a121/11758958/f868074b3b81/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a121/11758958/f05796d4baf7/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a121/11758958/be22de8f6712/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a121/11758958/c40bc0a31ee3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a121/11758958/f868074b3b81/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a121/11758958/f05796d4baf7/gr4.jpg

相似文献

1
"Evaluating the efficacy and safety of direct oral anticoagulants compared to warfarin in very morbidly obese patients with non-valvular atrial fibrillation: A retrospective cohort study".评估直接口服抗凝剂与华法林相比在极重度肥胖非瓣膜性心房颤动患者中的疗效和安全性：一项回顾性队列研究
Heliyon. 2025 Jan 3;11(1):e41596. doi: 10.1016/j.heliyon.2024.e41596. eCollection 2025 Jan 15.
2
A single center retrospective cohort study evaluating use of direct oral anticoagulants (DOACs) in morbidly obese veteran population.一项评估直接口服抗凝剂（DOACs）在病态肥胖退伍军人人群中应用的单中心回顾性队列研究。
Thromb Res. 2020 Aug;192:124-130. doi: 10.1016/j.thromres.2020.04.015. Epub 2020 Apr 16.
3
Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Nonvalvular Atrial Fibrillation: A Systematic Review and Meta-analysis.直接口服抗凝剂与华法林在病态肥胖非瓣膜性心房颤动患者中的比较：系统评价和荟萃分析。
Am J Ther. 2021 Jun 18;28(5):e531-e539. doi: 10.1097/MJT.0000000000001403.
4
The Efficacy and Safety of Direct Oral Anticoagulants Compared to Warfarin in Morbidly Obese Patients on Anticoagulation: A Systematic Review and Meta-Analysis.
Curr Vasc Pharmacol. 2025 Feb 11. doi: 10.2174/0115701611330090250130075810.
5
Comparing the Efficacy and Safety of Direct Oral Anticoagulants With Warfarin in the Morbidly Obese Population With Atrial Fibrillation.比较病态肥胖人群中房颤患者直接口服抗凝剂与华法林的疗效和安全性。
Ann Pharmacother. 2019 Feb;53(2):165-170. doi: 10.1177/1060028018796604. Epub 2018 Aug 22.
6
Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.评估直接口服抗凝剂（DOACs）与华法林相比在病态肥胖患者中的疗效。
Hosp Pract (1995). 2019 Oct;47(4):181-185. doi: 10.1080/21548331.2019.1674586. Epub 2019 Nov 5.
7
Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.与华法林相比，直接口服Xa因子抑制剂在病态肥胖患者中的疗效和安全性：一项单中心图表数据回顾性分析
Lancet Haematol. 2019 Jul;6(7):e359-e365. doi: 10.1016/S2352-3026(19)30086-9. Epub 2019 May 24.
8
Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Obese Patients with Atrial Fibrillation.肥胖症心房颤动患者中直接口服抗凝剂的疗效和安全性比较。
Cardiovasc Drugs Ther. 2021 Apr;35(2):261-272. doi: 10.1007/s10557-020-07126-2. Epub 2021 Jan 6.
9
Dose specific effectiveness and safety of DOACs in patients with non-valvular atrial fibrillation: A Canadian retrospective cohort study.非瓣膜性心房颤动患者 DOACs 的剂量特异性有效性和安全性：一项加拿大回顾性队列研究。
Thromb Res. 2021 Jul;203:121-130. doi: 10.1016/j.thromres.2021.05.005. Epub 2021 May 11.
10
Safety and efficacy of apixaban, dabigatran and rivaroxaban in obese and morbidly obese patients with heart failure and atrial fibrillation: A real-world analysis.阿哌沙班、达比加群和利伐沙班在肥胖及病态肥胖的心力衰竭合并心房颤动患者中的安全性和有效性：一项真实世界分析。
Pacing Clin Electrophysiol. 2023 Jan;46(1):50-58. doi: 10.1111/pace.14623. Epub 2022 Dec 1.

本文引用的文献

1
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2023 ACC/AHA/ACCP/HRS 指南：心房颤动的诊断与管理——美国心脏病学会/美国心脏协会联合临床实践指南委员会的报告。
Circulation. 2024 Jan 2;149(1):e1-e156. doi: 10.1161/CIR.0000000000001193. Epub 2023 Nov 30.
2
Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review.肥胖患者直接口服抗凝剂的药代动力学和给药方案：最新文献综述。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231153638. doi: 10.1177/10760296231153638.
3
Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.
直接口服抗凝药与华法林在心房颤动患者中的比较：按年龄和性别进行交互测试的随机临床试验的患者水平网络荟萃分析。
Circulation. 2022 Jan 25;145(4):242-255. doi: 10.1161/CIRCULATIONAHA.121.056355. Epub 2022 Jan 5.
4
Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO).肥胖与心房颤动患者的直接口服抗凝剂：意大利国家医院心脏病专家协会（ANMCO）立场文件
J Clin Med. 2021 Sep 16;10(18):4185. doi: 10.3390/jcm10184185.
5
Corrigendum to: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.勘误：《2021年欧洲心律协会心房颤动患者使用非维生素K拮抗剂口服抗凝剂实用指南》
Europace. 2021 Oct 9;23(10):1676. doi: 10.1093/europace/euab157.
6
Outcomes of Direct Oral Anticoagulants in Atrial Fibrillation Patients Across Different Body Mass Index Categories.不同体重指数类别中房颤患者直接口服抗凝剂的治疗结局。
JACC Clin Electrophysiol. 2021 May;7(5):649-658. doi: 10.1016/j.jacep.2021.02.002. Epub 2021 Mar 31.
7
Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.在体重处于极端范围的房颤患者中，阿哌沙班与华法林的疗效和安全性。
Circulation. 2019 May 14;139(20):2292-2300. doi: 10.1161/CIRCULATIONAHA.118.037955.
8
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.2019年美国心脏协会/美国心脏病学会/心律学会对2014年美国心脏协会/美国心脏病学会/心律学会心房颤动患者管理指南的聚焦更新：美国心脏病学会/美国心脏协会临床实践指南工作组和心律学会的报告
J Am Coll Cardiol. 2019 Jul 9;74(1):104-132. doi: 10.1016/j.jacc.2019.01.011. Epub 2019 Jan 28.
9
Peak plasma concentration of direct oral anticoagulants in obese patients weighing over 120 kilograms: A retrospective study.体重超过120公斤的肥胖患者中直接口服抗凝剂的血浆峰值浓度：一项回顾性研究。
Res Pract Thromb Haemost. 2018 Aug 29;2(4):684-688. doi: 10.1002/rth2.12146. eCollection 2018 Oct.
10
Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis.已批准用于心血管适应证的直接口服抗凝剂的疗效和安全性：系统评价和荟萃分析。
PLoS One. 2018 May 24;13(5):e0197583. doi: 10.1371/journal.pone.0197583. eCollection 2018.